To the full analysis
Sotera Health stock: growth
SHCSotera Health reported $1.16B in revenue for fiscal 2025, up 5.7% on the prior year, up 7.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
6.6%
per year from 2018 to 2025, per share 4.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
18%
per year from 2018 to 2025, per share 15.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2018 | |
|---|---|---|
| Revenue | 7.3% | 6.6% |
| Revenue per share | 7.2% | 4.4% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | 17.3% | 18.0% |
| Free cash flow per share | 17.3% | 15.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2018 | $746.15M | −$5.87M | $46.95M |
| 2019 | $778.33M | −$20.85M | $91.78M |
| 2020 | $818.16M | −$38.62M | $67.08M |
| 2021 | $931.48M | $116.88M | $179.38M |
| 2022 | $1B | −$233.57M | $95.58M |
| 2023 | $1.05B | $51.38M | −$362.71M |
| 2024 | $1.1B | $44.4M | $45.09M |
| 2025 | $1.16B | $77.95M | $149.18M |
Revenue by segment
How Sotera Health Company makes its money and how that has shifted. Names are as the company reports them.
- Service86%
- Product14%
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| Service | $805.5M | $864.83M | $905.6M | $941.82M | $995.76M | 85.6% |
| Product | $125.98M | $138.86M | $143.69M | $158.62M | $167.86M | 14.4% |
| Total revenue | $931.48M | $1B | $1.05B | $1.1B | $1.16B | 100% |
Revenue by region
Where Sotera Health Company generates its revenue.
- United States54%
- Europe20%
- Canada19%
- Other7%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| United States | $527.91M | $579.02M | $590.97M | $616.68M | $629.54M | 54.1% |
| Europe | $161.81M | $166.03M | $187.54M | $196.01M | $232.18M | 20% |
| Canada | $177.88M | $188.74M | $192.05M | $208.89M | $221.95M | 19.1% |
| Other | $63.89M | $69.9M | $78.73M | $78.86M | $79.95M | 6.9% |
| Total revenue | $931.48M | $1B | $1.05B | $1.1B | $1.16B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 20 Feb 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.